JP2019513826A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513826A5
JP2019513826A5 JP2019503597A JP2019503597A JP2019513826A5 JP 2019513826 A5 JP2019513826 A5 JP 2019513826A5 JP 2019503597 A JP2019503597 A JP 2019503597A JP 2019503597 A JP2019503597 A JP 2019503597A JP 2019513826 A5 JP2019513826 A5 JP 2019513826A5
Authority
JP
Japan
Prior art keywords
tumors
pharmaceutical composition
tumor
individual
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513826A (ja
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed filed Critical
Priority claimed from PCT/AU2017/050299 external-priority patent/WO2017173496A1/en
Publication of JP2019513826A publication Critical patent/JP2019513826A/ja
Publication of JP2019513826A5 publication Critical patent/JP2019513826A5/ja
Pending legal-status Critical Current

Links

JP2019503597A 2016-04-06 2017-04-06 放射線療法の改善 Pending JP2019513826A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762461559P 2017-02-21 2017-02-21
US62/461,559 2017-02-21
PCT/AU2017/050299 WO2017173496A1 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Publications (2)

Publication Number Publication Date
JP2019513826A JP2019513826A (ja) 2019-05-30
JP2019513826A5 true JP2019513826A5 (enExample) 2020-05-21

Family

ID=60000154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503597A Pending JP2019513826A (ja) 2016-04-06 2017-04-06 放射線療法の改善

Country Status (6)

Country Link
US (2) US11229703B2 (enExample)
EP (1) EP3439642A4 (enExample)
JP (1) JP2019513826A (enExample)
AU (1) AU2017247006B2 (enExample)
CA (1) CA3058492A1 (enExample)
WO (1) WO2017173496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
MXPA04009896A (es) 2002-04-09 2005-06-17 Novogen Res Pty Ltd Metodos terapeuticos y composiciones que implican estructuras de tipo isoflav-3-eno e isoflavano.
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
CN101123958A (zh) * 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
US20050154452A1 (en) 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1809618B1 (en) 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ATE532777T1 (de) * 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
US20090131513A1 (en) 2005-03-24 2009-05-21 Novogen Research Pty Ltd. Anti-inflammatory modalities
JP2009508869A (ja) 2005-09-15 2009-03-05 ユーエムディー， インコーポレイテッド シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
WO2008052256A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
EP2160385A4 (en) * 2007-06-29 2010-10-27 Novogen Res Pty Ltd 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND MEDICAMENTS THEREOF AND APPLICATIONS THEREOF
US20120039917A1 (en) 2008-08-29 2012-02-16 Alan James Husband Immunomodulating activities
US8729134B2 (en) 2008-11-14 2014-05-20 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2766500A4 (en) * 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
ES2734568T3 (es) * 2013-03-13 2019-12-10 Oncoceutics Inc 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
SG11201604490SA (en) * 2014-02-07 2016-07-28 Novogen ltd Functionalised benzopyran compounds and use thereof
SG10202111808WA (en) 2015-08-11 2021-11-29 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CN108884159A (zh) * 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2016401508B2 (en) * 2016-04-06 2020-03-26 Noxopharm Limited Improvements in cancer treatment
EP4035667A1 (en) * 2016-04-22 2022-08-03 Noxopharm Limited Chemotherapy improvements with idronoxil
JP7329860B2 (ja) 2018-06-15 2023-08-21 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｓ－エクオールを用いた乳癌の治療及び予防方法
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Similar Documents

Publication Publication Date Title
Verma Relationship and interactions of curcumin with radiation therapy
JP2018502120A5 (enExample)
JP2016536286A5 (enExample)
JP2019504105A5 (enExample)
US20160113884A1 (en) Preparation method of radiation sensitive copolymer carrier for coating radiated nanoparticles and chemotherapy drugs
CN107303411A (zh) 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统
Helm et al. Combining heavy-ion therapy with immunotherapy: an update on recent developments
JP2016524602A5 (enExample)
Marjanovic et al. Acute toxicity of postoperative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy
JP2019513826A5 (enExample)
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
Durant Cisplatin: a clinical overview
JP2012527424A5 (enExample)
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
Huart et al. Could protons and carbon ions be the silver bullets against pancreatic cancer?
Zhang et al. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
JP2018199726A5 (enExample)
JP2016514142A5 (enExample)
Sartor et al. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered
KR102063397B1 (ko) Pfi-3를 포함하는 폐암 또는 대장암의 예방 또는 치료용 조성물
Taylor et al. Children's Cancer and Leukemia Group (CCLG) Study of Hyperfractionated Accelerated Radiotherapy (HART) with Chemotherapy for M1–3 Medulloblastoma (MB)
JP2020506886A5 (enExample)
Wilkins et al. PO-0720: Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257)
Li et al. A retrospective study of hypofractionated radiotherapy for small cell lung cancer